You just read:

Phoenix Molecular Designs Initiates its Phase 1/1b Program to Evaluate PMD-026 in Patients with Resistant Forms of Advanced Breast Cancer

News provided by

Phoenix Molecular Designs

Nov 20, 2019, 08:00 ET